Sprout Health

What the Sprout Health Intake Looks Like

We walked through Sprout Health’s intake ourselves, from the opening weight-loss goal through a notably thorough contraindication checklist, self-reported BP and heart rate screens, an explicit opioid gate, and finally the three-medication shelf and checkout with a pre-applied $150-off coupon.

Sprout puts three of the category’s most undersurveyed safety signals on screen before any prescription can be issued: an explicit eating disorder gate (anorexia/bulimia), an explicit current suicidal thoughts and/or prior suicidal attempt gate, and a dedicated opioid screen that names opiate pain medications AND opiate-based street drugs as separate items. Each of these is clinically relevant — GLP-1 appetite suppression can destabilize restrictive eating patterns, any weight-loss or mood-relevant medication warrants a baseline suicide risk check, and opioids interact with GI motility the same way GLP-1s do. Very few GLP-1 telehealth intakes surface all three.

Sprout’s cancer gate is more nuanced than the category norm. Instead of a blanket “do you have cancer,” the question reads: “Cancer (active diagnosis, active treatment, or in remission or cancer-free for less than 5 continuous years; doesn’t apply to non-melanoma skin cancer that was considered cured via simple excision alone).” That’s clinically meaningful — oncology guidelines often use 5-year remission as a recurrence threshold, and non-melanoma skin cancer is broadly considered low-risk once excised. Writing the gate this way lets Sprout keep safe candidates in the funnel without dropping patients with a decade-old remote history.

Very few GLP-1 intakes ask the patient to self-report blood pressure and resting heart rate ranges. Sprout does — with four-tier ordinal scales (BP: normal → Stage 2, HR: slow → fast) and an explicit “I’m not sure” option. It’s not a substitute for a real measurement at a visit, but it’s a legitimate screening signal and a helpful trigger for the async clinician review.

For all of Sprout’s strengths on mental health, substance use, and vital-sign self-report, the intake in our walkthrough did not include a personal or family history screen for medullary thyroid cancer or MEN2 syndrome, and no explicit pancreatitis history question. Both are FDA-black-box-relevant and appear in the majority of GLP-1 telehealth intakes we’ve audited. A severe-GI gate is present (gastroparesis / blockage / IBD), but that doesn’t cover pancreatitis specifically. Patients with either risk factor should surface it to the clinician during async review before the first dose.

The entire flow runs under a persistent “$150 OFF YOUR FIRST MONTH (CODE: FIRST150)” banner, and the coupon is already applied at checkout — Semaglutide Injection drops from $299 to $149, Tirzepatide Injection and Tablets from $349 to $199. A 14:55 reserved-cart countdown holds the cart while you enter billing. Payment is a standard WooCommerce-style form with SSL-secured checkout badges and a “Purchase with confidence” block (Clinician-Prescribed, Privacy and Security, Easy Support). It’s one of the fastest paths from landing page to a funded prescription in our catalog.

Opens joinsprouthealth.com in a new tab. We may earn a commission if you start treatment through this link, at no additional cost to you.